A European-Multicenter Network for the Implementation of Artificial Intelligence to Manage Complexity and Comorbidities of Atrial Fibrillation Patients: The ARISTOTELES Consortium

Thrombosis and Haemostasis, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 20, 2025

Atrial fibrillation (AF) is the most common arrhythmia worldwide, contributing significantly to morbidity, healthcare costs, and resource utilization.[1] Patients with AF face a higher mortality morbidity from stroke, heart failure, dementia, hospitalizations.[1] Oral anticoagulants (OACs) are cornerstone of management, as they substantially reduce risk stroke mortality.[2] Nevertheless, some residual still remains despite anticoagulation, AF-related linked cardiovascular causes comorbidities rather than alone.[2] [3]

Language: Английский

---

Myths and challenges around anticoagulation in atrial fibrillation: A practicing clinician's perspective

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 21, 2025

KEJA: Speaker: Bayer, Pfizer and Boehringer-Ingelheim. Research grants from the Finnish Foundation for Cardiovascular Clinical Fund of Turku University Hospital; VL: grant State Funding Hospital expert responsibility area; KT: none. GYHL: Consultant speaker BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute Health Care (NIHR) Senior Investigator co-PI AFFIRMO project on multimorbidity in AF (grant agreement 899871), TARGET digital twins personalized management atrial fibrillation stroke 101136244) ARISTOTELES artificial intelligence chronic long-term conditions 101080189), which all funded by EU's Horizon Europe & Innovation programme. Perspective article based interpretation articles reference list. Data used to support findings this study available corresponding author upon request.

Language: Английский

---

Peripheral artery disease, antithrombotic treatment and outcomes in European and Asian patients with atrial fibrillation: analysis from two prospective observational registries

BMC Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Dec. 2, 2024

Language: Английский

---

Welcoming 2025—A Year of Collaboration and Progress

Thrombosis and Haemostasis, Journal Year: 2025, Volume and Issue: 125(01), P. 001 - 002

Published: Jan. 1, 2025

As we begin 2025, it is a time to reflect on our journey and the exciting initiatives that continue shape future of Thrombosis & Haemostasis. This editorial offers moment celebrate recent achievements introduce new strategies, collaborations, opportunities look forward in year ahead.

Language: Английский

---

Thrombosis and Haemostasis 2024 Editors' Choice Papers

Thrombosis and Haemostasis, Journal Year: 2025, Volume and Issue: 125(01), P. 085 - 091

Published: Jan. 1, 2025

This year's Editors' Choice highlights some of the most impactful 2024 publications in Thrombosis and Haemostasis (TH) its open-access companion journal TH Open.The selection reflects key trends field, including new guidelines, emerging therapies, diagnostic technologies reshaping treatment approaches as well practical challenges related to implementation, adherence, patient outcomes.Additionally, role genetics, lifestyle, recently emerged conditions such COVID-19 thrombosis came forefront research published last year.

Language: Английский

---

Left Atrial Appendage Occlusion in Patients Receiving Hemodialysis

JACC Asia, Journal Year: 2025, Volume and Issue: 5(1), P. 187 - 190

Published: Jan. 1, 2025

Language: Английский

---

Early Rhythm Control Therapy in Patients With Atrial Fibrillation—Kidney Function Matters

Mayo Clinic Proceedings, Journal Year: 2025, Volume and Issue: 100(4), P. 599 - 602

Published: April 1, 2025

Language: Английский

---

Effects of the ABC pathway on clinical outcomes in very elderly Chinese patients with atrial fibrillation. A report from the optimal thromboprophylaxis in elderly Chinese patients with atrial fibrillation (ChiOTEAF) registry

Internal and Emergency Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: April 27, 2025

Abstract The current Atrial fibrillation Better Care (ABC) pathway for holistic or integrated management of AF is associated with improved clinical outcomes; however, data on the very elderly (aged ≥ 85 years) are sparse. To evaluate impact ABC outcomes amongst patients over a follow-up period 1 year. ChiOTEAF registry prospective, multicenter nationwide study conducted from October 2014 to December 2018. Endpoints interest were composite outcome all-cause death/any thromboembolism (TE), death, TE events, and major bleeding. eligible cohort included 1215 individuals (mean age 88.5 ± 3.3; 33.5% female), which 142 (11.7%) managed accordingly pathway. compliance was independently lower odds (odds Ratio (OR): 0.23; 95% confidence interval (CI): 0.08–0.66) death (OR: 0.22; CI: 0.07–0.75), without significant increase in bleeding compared non-compliance. Health-related quality life (QOL) also significantly higher compliant group non-compliant (EQ score 0.83 0.17 vs. 0.78 0.20; p = 0.004). Independent predictors non-compliance prior bleeding, chronic kidney disease, dementia. Our findings suggest that adherence survival health-related QOL.

Language: Английский

---

Left atrial low voltage areas predicts clinical stroke after radiofrequency ablation in patients with atrial fibrillation

International Journal of Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 133366 - 133366

Published: May 1, 2025

Language: Английский

---

Adherence to the ABC (atrial fibrillation better care) pathway and risk of adverse outcomes in patients with chronic kidney disease: a report from the prospective APHRS-AF registry

The Lancet Regional Health - Western Pacific, Journal Year: 2025, Volume and Issue: 58, P. 101570 - 101570

Published: May 1, 2025

Language: Английский

---